ASH 2016 | New targets for hematological malignancy therapies
Olaf Heidenreich, PhD from Newcastle University, Newcastle, UK discusses what he finds most exciting about the new treatments in cancer and hematology. He talks about the neglected connection between epigenetics and genomics, to the classical biochemistry of metabolism. This renewed focus on ‘old-fashioned’ biochemistry brings up a plethora of new and exciting targets for cancer therapy and hematology. Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.
Get great new content delivered to your inboxSign up